Alnylam Pharmaceuticals Inc
(NAS:ALNY)
$
266.255
-2.695 (-1%)
Market Cap: 34.34 Bil
Enterprise Value: 33.29 Bil
PE Ratio: 0
PB Ratio: 1,065.02
GF Score: 78/100 Alnylam Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference Transcript
May 16, 2019 / 04:20PM GMT
Release Date Price:
$68.73
(+0.97%)
Ying Huang
BofA Merrill Lynch, Research Division - Director in Equity Research
Thank you so much for being here at the last day of our Healthcare Conference in Vegas. Welcome, everyone. My name is Chen Huang, and I'm on the large cap biotech team here at BAML. And today, it's my pleasure to have Alnylam here with us with a discussion, which I'm looking forward to.
And we're having Dr. John Maraganore, the CEO of Alnylam, and thank you so much for coming today.
John M. Maraganore
Alnylam Pharmaceuticals, Inc. - CEO & Executive Director
Thank you, Chen. It's great to be here.
Questions & Answers
Ying Huang
BofA Merrill Lynch, Research Division - Director in Equity Research
So maybe we can just start with your launch on ONPATTRO because it's definitely a big milestone for a company like you to get to approval and launching today. And the drug has been approved on the market for a few quarters now. Would you just generally talk about the launch overall and how do you feel about it?
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot